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Abstract
Background: The extent to which susceptibility to brain hemorrhage is derived from blood-derived factors or
stromal tissue remains largely unknown. We have developed an inducible model of CD8 T cell-initiated blood-brain
barrier (BBB) disruption using a variation of the Theiler’s murine encephalomyelitis virus (TMEV) model of multiple
sclerosis. This peptide-induced fatal syndrome (PIFS) model results in severe central nervous system (CNS) vascular
permeability and death in the C57BL/6 mouse strain, but not in the 129 SvIm mouse strain, despite the two strains’
having indistinguishable CD8 T-cell responses. Therefore, we hypothesize that hematopoietic factors contribute to
susceptibility to brain hemorrhage, CNS vascular permeability and death following induction of PIFS.
Methods: PIFS was induced by intravenous injection of VP2121-130 peptide at 7 days post-TMEV infection. We then
investigated brain inflammation, astrocyte activation, vascular permeability, functional deficit and microhemorrhage
formation using T2*-weighted magnetic resonance imaging (MRI) in C57BL/6 and 129 SvIm mice. To investigate
the contribution of hematopoietic cells in this model, hemorrhage-resistant 129 SvIm mice were reconstituted with
C57BL/6 or autologous 129 SvIm bone marrow. Gadolinium-enhanced, T1-weighted MRI was used to visualize the
extent of CNS vascular permeability after bone marrow transfer.
Results: C57BL/6 and 129 SvIm mice had similar inflammation in the CNS during acute infection. After
administration of VP2121-130 peptide, however, C57BL/6 mice had increased astrocyte activation, CNS vascular
permeability, microhemorrhage formation and functional deficits compared to 129 SvIm mice. The 129 SvIm mice
reconstituted with C57BL/6 but not autologous bone marrow had increased microhemorrhage formation as
measured by T2*-weighted MRI, exhibited a profound increase in CNS vascular permeability as measured by three-
dimensional volumetric analysis of gadolinium-enhanced, T1-weighted MRI, and became moribund in this model
system.
Conclusion: C57BL/6 mice are highly susceptible to microhemorrhage formation, severe CNS vascular permeability
and morbidity compared to the 129 SvIm mouse. This susceptibility is transferable with the bone marrow
compartment, demonstrating that hematopoietic factors are responsible for the onset of brain microhemorrhage
and vascular permeability in immune-mediated fatal BBB disruption.
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Unregulated permeability of the blood-brain barrier
(BBB) is a feature of many neurological diseases as
diverse as stroke, viral hemorrhagic fevers, HIV demen-
tia, shock, cerebral malaria, multiple sclerosis, acute
hemorrhagic leukoencephalitis and epilepsy [1-16]. An
impermeable BBB is a major obstacle to effective thera-
peutic delivery of chemotherapy [17]. There is increas-
ing evidence that inflammatory mediators expressed by
central nervous system (CNS) infiltrating immune cells
contribute to BBB permeability [6,18-20]. The mechan-
ism by which blood-derived factors and tissue stromal
cells contribute to CNS vascular permeability in vivo
remain undefined, however, indicating that inflamma-
tion-driven BBB permeability is a complex condition.
For all the above reasons, developing model systems to
define inflammatory mediators involved in susceptibility
and resistance to BBB disruption could ultimately lead
to the discovery of novel therapeutics designed to both
intervene with and augment CNS vascular permeability.
Clinical observations and rodent models support a
role for inflammatory immune cells in promoting open-
ing of the BBB. Monocytes and neutrophils have been
demonstrated to contribute to CNS vascular permeabil-
ity [21]. CD4 T-cell subsets have also been implicated in
BBB disruption, including the demonstration of tight
junction protein alterations that are initiated by TH17
cells [22,23]. Our studies have defined antigen-specific
CD8 T cells as an additional potent mediator of rapid
BBB disruption [24-27]. The concept that CD8 T cells
and high antigenic peptide load promote an important
link between inflammatory disease and vascular perme-
ability is further supported by numerous studies in cere-
bral malaria and viral hemorrhagic fevers [13,16,28-33].
In addition, CD8 T cells are a major lymphocyte subset
observed in multiple sclerosis lesions characterized by
the presence of gadolinium enhancement visible by
magnetic resonance imaging (MRI) [34,35]. However,
the extent to which these different immune cell types
utilize common mechanisms to promote BBB disruption
remains unknown. The extent to which susceptibility to
brain hemorrhage is due to blood-derived factors or
stromal tissue also remains unknown.
Our model of CD8 T-cell-initiated BBB disruption uti-
lizes a variation of the Theiler’s murine encephalomyeli-
tis virus (TMEV) model commonly used to study
multiple sclerosis [24-27]. During acute TMEV infec-
tion, 50% to 70% of CNS-infiltrating CD8 T cells in the
C57BL/6 mouse are specific for an immunodominant
virus peptide, VP2121-130 (FHAGSLLVFM), presented in
the context of the D
b class I molecule. The peak expan-
sion of D
b:V P 2 121-130 epitope-specific CD8 T cells is 7
days postinfection and is predominantly limited to the
CNS [36]. Intravenous injection of VP2121-130 peptide at
7 days post-TMEV infection results in activation of
astrocytes and microglia, alteration of tight junction pro-
teins, extensive CNS vascular permeability and func-
tional deficit in the C57BL/6 mouse [24-27]. Vascular
permeability is perforin-dependent and exclusive to the
C N S ,t h es i t eo fD
b:V P 2 121-130 epitope-specific CD8 T
cell expansion [24,25]. In this model, BBB disruption is
followed by death approximately 48 to 72 hours later.
We have termed this condition “peptide-induced fatal
syndrome” (PIFS).
The PIFS model is inducible with administration of
VP2121-130 peptide, enabling the study of early and late
gene expression events during immune-mediated BBB
disruption in the C57BL/6 mouse strain. In contrast to
C57BL/6 mice, 129 SvIm mice are resistant to PIFS,
despite this strain’s having an indistinguishable CNS-
infiltrating D
b:V P 2 121-130 epitope-specific CD8 T-cell
response. In this study, we evaluated the differential
effects of CD8 T cells in initiating CNS vascular perme-
ability in these two strains. We also employed the PIFS
model system to address the extent to which blood-
derived factors or CNS stromal tissues contribute to
functional deficit, microhemorrhage formation and CNS
vascular permeability.
Methods
Animals
The mouse strains C57BL/6 (strain 000664; The Jackson
Laboratory, Bar Harbor, ME, USA) and 129 SvIm (strain
002448; The Jackson Laboratory) were used in this
study because of their differential susceptibility to [27].
All mice were obtained at 6 weeks of age. All experi-
ments were approved by the Institutional Animal Care
and Use Committees of the University of Cincinnati and
the Mayo Clinic.
In vitro cytotoxic T lymphocyte assay
C57SV cells transfected with the genes encoding the
TMEV protein VP2 were used as targets, as previously
described [37]. A standard 4-hour
51Cr release assay was
done to determine cytotoxic T lymphocyte (CTL) activ-
ity in CNS-infiltrating lymphocyte preparations obtained
from C57BL/6 and 129 SvIm mice. Untransfected and
VP2 gene-transfected C57SV cells were labeled with
51Cr for 2 hours. Freshly isolated effector cells were
incubated with labeled target cells for 4 hours. The per-
centage specific lysis of target cells was calculated from
released
51Cr as follows: 100 × (experimental release -
spontaneous release)/(total release in detergent - sponta-
neous release). The number of effector T cells added
was estimated by counting the cells with lymphocyte
morphology by microscopic inspection.
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vascular permeability
CNS vascular permeability was induced as described
previously [27]. Briefly, all mice were intracranially
infected with 2 × 10
6 plaque-forming units of Daniel’s
strain of TMEV. Seven days post-TMEV infection mice
were injected intravenously with 0.1 mg of VP2121-130
(FHAGSLLVFM) to induce CNS vascular permeability
or mock control E7 (RAHYNIVTF) peptide (GenScript,
Piscataway, NJ, USA).
Flow cytometry
Seven days post-TMEV infection, brain-infiltrating lym-
phocytes were isolated from mouse brains by collage-
nase digestion and a Percoll gradient as previously
described [38]. Allophycocyanin (APC) D
b:V P 2 121-130
tetramer and APC D
b: E7 tetramer were constructed as
previously described and used in conjunction with anti-
CD8-fluorescein isothiocyanate (FITC) (553031; BD
Pharmingen, San Diego, CA, USA) and anti-CD45
(557235; BD Pharmingen) [23]. Neutrophils were
assessed by staining with anti-Ly6G antibody (127603;
BioLegend, San Diego, CA, USA) conjugated with phy-
coerythrin-streptavidin (Invitrogen, Carlsbad, CA, USA).
Samples were read on a BD LSR II Flow Cytometer (BD
Biosciences, San Jose, CA, USA) and analyzed with BD
FACSDiva version 6.0 software (BD Biosciences).
Rotarod
Animals were placed on the Rotamex-5 rotarod appara-
tus (Columbus Instruments, Columbus, OH, USA), with
the speed increased from 5 to 40 rpm over 7 minutes as
previously described [39]. Animals were trained twice
daily for 3 days. On the final day, a baseline ability in
seconds remaining on the rotarod was determined for
each mouse. Twenty-four hours following administra-
tion of VP2121-130 peptide, a rotarod score in seconds
was determined. Functional ability was represented as
percentage initial ability on the rotarod using the for-
mula: 100% × (seconds on rotarod prior to VP2 peptide
administration)/(seconds on rotarod 24 hours post-VP2
peptide administration).
Western blot analysis
Brain tissue samples were lysed in radioimmunoprecipi-
tation assay buffer [25] (10 mmol/L Tris, 140 mmol/L
NaCl, 1% Triton X-100, 1% Na
+ deoxycholate, 0.1% SDS
and protease inhibitor cocktail (78410; Pierce Biotech-
nology, Rockford, IL, USA), pH 7.5) and centrifuged for
15 minutes at 10,000 rpm. Samples were normalized for
protein content after protein concentration was assessed
using a bicinchoninic acid protein assay (23223; Pierce
Biotechnology). For glial fibrillary acidic protein (GFAP)
detection, 10 μg of protein per well were loaded onto
4% to 20% precise protein gels (25244; Pierce Biotech-
nology) with BupH Tris-4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid-SDS running buffer (28398; Pierce
Biotechnology). Gels were transferred onto Immun-Blot
LF polyvinylidene fluoride membranes (162-0177; Bio-
Rad Laboratories, Hercules, CA, USA) using Tris trans-
fer buffer (400 mmol/ml Tris base, 70 mmol/ml glycine
and 10% methanol). Mouse anti-GFAP (1:1,000 dilution,
556329; BD Pharmingen) and goat anti-mouse immuno-
globulin G conjugated to horseradish peroxidase were
used to detect GFAP (A3682; Sigma-Aldrich, St Louis,
MO, USA). Western blot films were analyzed by densi-
tometry using Scion Image software (Scion Corp, Fre-
derick, MD, USA). Background was subtracted from
each band, and data are expressed in arbitrary units.
Fluorescein isothiocyanate-albumin permeability assay
Mice were injected intravenously with 10 mg of FITC-
albumin (A9771; Sigma-Aldrich) 23 hours after VP2121-
130 peptide administration to induce PIFS. Brains were
harvested 1 hour after administration of FITC-albumin
and frozen on aluminum foil on dry ice. The right hemi-
sphere was homogenized with radioimmunoprecipitation
assay buffer as described above using Western blot
methodology. Homogenates were read on a fluorescent
plate reader at 488-nm excitation and 525-nm emission
to detect FITC-albumin leakage into the brain. Data
were collected using SpectraMax software (Molecular
Devices, Sunnyvale, CA, USA).
Bone marrow transplants
To determine the contribution of C57BL/6 hematopoie-
tic cells to susceptibility to PIFS and microhemorrhage
formation, 8-week-old male 129 SvIm mice were lethally
irradiated with two pulses of 700 and 425 rad 4 hours
apart. Twenty-four hours later 129 Svlm mice were
intravenously reconstituted with 10
7 autologous bone
marrow or C57BL/6 Ly5.1
+ bone marrow-derived cells.
Eight weeks postreconstitution, mice were infected with
TMEV. Seven days post-TMEV infection, animals were
administered VP2121-130 peptide and analyzed for sus-
ceptibility to PIFS. A similar protocol was followed to
determine the contribution of C57BL/6 hematopoietic
cells to susceptibility to functional deficit and CNS vas-
cular permeability, except that 129 Svlm mice were
reconstituted with 10
7 autologous bone marrow or
C57BL/6 Ly5.1
+ bone marrow-derived cells at 5 weeks
of age and infected with TMEV at 4 weeks postreconsti-
tution. Animals were administered VP2121-130 peptide 7
days post-TMEV infection.
Magnetic resonance imaging
In vivo MRI was performed in a 7-Tesla narrow-bore
small animal imaging system (Bruker BioSpin, Billerica,
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A custom-made saddle coil was employed for acquisi-
tion and excitation. We acquired three-dimensional,
T2*-weighted images (gradient echo fast imaging pulse
sequence: repetition time (TR) = 150 ms, echo time
(TE) = 10 ms, flip angle = 15°, field of view = 4 × 2.5 ×
2.5 cm, matrix: 256 × 128 × 128, number of excitations
= 4). MRI scans were analyzed using Analyze (Biomedi-
cal Imaging Resource, Mayo Clinic, Rochester, MN,
USA) and ImageJ software (National Institutes of
Health, Bethesda, MD, USA). A blinded technician
using Analyze captured axial slices from each animal.
Axial slices representing z = 0 according to stereotactic
coordinate criteria put forward by Kovacevic et al. [40]
were obtained using Analyze. These axial slices were
then analyzed using ImageJ software to enable threshold
analysis and densitometric analysis. Only T2*-weighted
MRI lesions obtained from animals not representative of
common brain structures (that is, ventricles) were quan-
tified. Once data were obtained, the total T2*-weighted
MRI lesion load as a percentage of whole brain was
determined for each axial slice. Samples were then
unblinded, and the T2*-weighted MRI lesion loads
among animals in the different experimental groups
were determined. Additionally, a Bruker Avance II 7-
Tesla vertical bore small-animal MRI system (Bruker
B i o S p i n )w a su s e dt oa c q u i r eT 1 - w e i g h t e di m a g e st o
evaluate CNS vascular permeability. Image acquisition
was performed as described previously [26,41]. Mice
were given an intraperitoneal injection of gadolinium
using weight-based dosing of 100 mg/kg. After a stan-
dard delay of 15 minutes, a volume acquisition T1-
weighted spin-echo sequence was used (TR = 300 ms,
TE = 9.5 ms, FOV = 32 × 19.2 × 19.2 mm, matrix =
192 × 96 × 96, number of averages = 1) to obtain T1-
weighted images. Analyze 10 software (Biomedical Ima-
ging Resource, Mayo Clinic) was used to quantify the
three-dimensional volume of vascular permeability as
previously described [42-44]. The three-dimensional
volume extractor tool was employed to extract brains
from the gadolinium-enhanced, T1-weighted images.
Areas of gadolinium leakage were defined using semiau-
tomated methods in the three-dimensional region of
interest tool. The identified volume of gadolinium
enhancement was saved as a three-dimensional object,
then the three-dimensional sampling tool was used to
calculate the actual volume of this object. Figures were
generated by performing three-dimensional object ren-
dering using the volume-rendering tool to visualize the
volume of contrast enhancement.
Statistical analysis
Mean and standard error values for rotarod scores, FITC-
albumin quantification, Western blot quantification and
quantification of the three-dimensional volume of gadoli-
nium leakage from vasculature were calculated using the
SigmaStat software program (SYSTAT Software Inc, Chi-
cago, IL, USA). Bar graphs with standard error values
were plotted using the SigmaPlot software program
(SYSTAT Software Inc). To determine the significance
level between groups, a Student’s t-test was performed
between E7 and VP2121-130 within the same strain using
SigmaPlot software. A Student’s t-test was also per-
formed to determine the significance level between the
bone marrow transplant groups.
Results
Comparable D
b: VP2121-130 epitope dominance among
CD8 T cells and neutrophil recruitment in C57BL/6 and
129 SvIm mouse strains
Seven days post-intracranial infection with TMEV,
C57BL/6 mice developed a robust CNS-infiltrating CD8
T-cell response toward the virus peptide VP2121-130 pre-
sented in the context of the D
b class I molecule. Using
D
b: VP2121-130 peptide major histocompatibility complex
(MHC) tetramers, we determined that 50% to 70% of
CNS-infiltrating CD8 T cells are specific for the D
b:
VP2121-130 epitope (Figures 1A and 1D) [36,39]. Similar
to C57BL/6 mice, 129 SvIm mice displayed comparable
levels of epitope dominance, including a similar percen-
tage of CD45
+ inflammatory infiltrate (Figures 1B and
1D). Figure 1C depicts a representative D
b: E7 peptide
MHC tetramer-negative staining control. CNS-infiltrat-
ing lymphocytes isolated from both strains exhibited
comparable levels of perforin-mediated cytotoxic killing
at 7 days post-TMEV infection (Figure 1E). Neutrophil
infiltration as measured by anti-Ly6G staining was also
similar between these two strains (n = 5 per strain) (Fig-
ures 1F through 1H). In 1,000,000 events recorded, we
did not observe statistically significant differences in
CNS-infiltrating CD45
+,L y 6 G
+,C D 8
+,o rC D 8
+ D
b:
VP2121-130 tetramer-positive cells isolated from the
brains of C57BL/6 and 129 SvIm mice (Figure 1; data
not shown). These data demonstrate that both of these
mouse strains mount a similar and functional D
b:
VP2121-130 epitope-specific CD8 T-cell-mediated
response to TMEV infection.
Functional deficit in C57BL/6 but not 129 SvIm mice
following induction of peptide-induced fatal syndrome
We previously published data showing that 7-day
TMEV-infected C57BL/6 mice that are intravenously
administered the VP2121-130 peptide epitope during the
peak of the VP2121-130 CD8 T-cell response succumb to
a fatal syndrome characterized by extensive CNS vascu-
lar permeability and microhemorrhage formation
[24-27]. In contrast, the 129 SvIm mouse strain, despite
having comparable expansion of D
b:V P 2 121-130 epitope-
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b: VP2121-130 epitope dominance among CNS-infiltrating CD8 T cells and neutrophil infiltration during acute TMEV infection.
Central nervous system (CNS)-infiltrating lymphocytes were isolated 7 days post-Theiler’s murine encephalomyelitis virus (TMEV) infection. Shown
is fluorescence-activated cell-sorting analysis staining for CD8 and D
b: VP2121-130 peptide tetramer among CNS-infiltrating lymphocytes isolated
from a representative (A) C57BL/6 mouse or (B) 129 SvIm mouse. (C) CNS-infiltrating C57BL/6 lymphocytes stained for CD8 and negative control
D
b: E7 peptide tetramer. (D) C57BL/6 and 129 Svlm mice display comparable levels of brain-infiltrating CD45
+ cells that are CD8
+ and specific for
the D
b: VP2121-130 epitope. (E) Equivalent capacity of CNS-infiltrating cytotoxic T lymphocytes isolated from TMEV-infected C57BL/6 and 129 SvIm
mice to utilize perforin to kill VP2-transfected C57SV target cells in a chromium release assay. Untransfected C57SV cells served as a negative
control. CD45
hi population was gated and analyzed for the percentage of Ly6G
+ cells in both (F) C57BL/6 and (G) 129 Svlm mice (n = 5 per
group). (H) Bar chart showing that C57BL/6 and 129 Svlm mice display comparable levels of Ly6G
+ cells, which are indicative of being a
neutrophil subset. In 1 million isolated total cells recorded by flow cytometry, there were no statistically significant differences in CD45
+, Ly6G
+,
or CD8
+ D
b: VP2121-130 tetramer-positive cells collected (data not shown).
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to this fatal syndrome. To quantify the severe functional
deficits that develop in mice with PIFS, we assessed
rotarod performance. At 24 hours after induction of
PIFS, C57BL/6 mice (n = 16) ran at 12% of their initial
ability. By comparison, 129 SvIm mice 24 hours after
administration of VP2121-130 peptide (n =1 6 )n e g o t i a t e
the rotarod at their initial ability level (Figure 2). This
experiment demonstrates that, despite mounting a com-
parable CD8 T-cell response restricted toward the D
b:
VP2121-130 epitope (Figure 1), only C57BL/6 mice
develop severe functional deficit that ultimately proceeds
to the animals’ becoming moribund.
Enhanced astrocyte glial fibrillary acidic protein
expression in C57BL/6 mice, but not in 129 SvIm mice,
following administration of VP2121-130 peptide
Astrocyte activation, as measured by GFAP expression,
colocalizes with vascular permeability in C57BL/6 mice
with PIFS [24]. To determine the extent to which astro-
cytes were activated in C57BL/6 and 129 SvIm mice in
the PIFS model, we evaluated (by quantitative Western
blot analysis) GFAP levels in animals that had been admi-
nistered E7 or VP2121-130 peptide (n = 6 per group). In
Figure 3, we present significantly upregulated GFAP
expression in VP2121-130 peptide-treated C57BL/6 mice
with PIFS compared to mock E7 peptide-treated controls.
GFAP expression in VP2121-130 peptide-treated C57BL/6
mice was also significantly higher than that in 129 SvIm
mice that were administered either E7 or VP2121-130 pep-
tide (Figure 3). This experiment demonstrated that, in
addition to becoming moribund, C57BL/6 mice induced
to develop PIFS had significantly higher GFAP expres-
sion, which is indicative of higher levels of astrocyte acti-
vation, than 129 SvIm mice did.
C57BL/6 mice have increased central nervous system
vascular permeability compared to 129 SvIm mice upon
induction of peptide-induced fatal syndrome
Seven-day TMEV-infected C57BL/6 mice administered
VP2121-130 p e p t i d et oi n d u c eP I F Sh a v eh i g hl e v e l so f
CNS vascular permeability [24]. To determine the extent
to which C57BL/6 mice have increased CNS vascular
permeability compared to 129 SvIm mice, we infected
these two strains with TMEV. Seven days later we admi-
nistered mock E7 peptide or VP2121-130 peptide to induce
PIFS (n = 6 per group). Animals were injected with
FITC-albumin 23 hours after administration of mock E7
peptide or VP2121-130 peptide and allowed to circulate for
1 hour. Brains were then harvested, homogenized and
measured for permeability of FITC-albumin into the
CNS according to our previously described methods
[24,25]. As shown in Figure 4, VP2121-130 peptide-treated
C57BL/6 and 129 SvIm mice had increased FITC-albu-
min leakage compared to mock E7 peptide-treated con-
trols. However, significantly higher permeability was
observed in C57BL/6 mice compared to 129 SvIm mice
after both had received VP2121-130 peptide administra-
tion. Additionally, we have previously described that
vascular endothelial growth factor (VEGF) contributes to
vascular permeability in C57BL/6 mice following admin-
istration of VP2121-130 peptide [25]. We therefore
assessed VEGF levels using Western blot analysis and
found that there was a significant increase in VEGF
Figure 2 C57BL/6 mice with peptide-induced fatal syndrome are unable to negotiate the rotarod. Seven-day Theiler’sm u r i n e
encephalomyelitis virus-infected C57BL/6 and 129 SvIm mice were intravenously administered VP2121-130 peptide. Rotarod performance is plotted
as the percentage of initial rotarod score prior to VP2121-130 peptide administration (n = 16 for each group).
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tered VP2 121-130 peptide compared to C57BL/6 mice
administered mock E7 peptide (P = 0.045). However,
there was no significant difference between 7-day
TMEV-infected 129 Svlm mice administered VP2121-130
or E7 peptide (P = 0.998) (data not shown). This increase
in VEGF in VP2121-130-treated C57BL/6 mice may contri-
bute to the significantly higher vascular permeability seen
in these mice, as previously described [25].
C57BL/6 mice with peptide-induced fatal syndrome have
greater microhemorrhage formation than 129 SvIm mice
as measured by T2*-weighted magnetic resonance
imaging
C57BL/6 mice present with higher CNS vascular perme-
ability than 129 SvIm mice, which may be dependent on
increased VEGF expression. Nevertheless, the observation
that both C57BL/6 and 129 SvIm mice have measurable
increases in CNS vascular permeability as measured by
FITC-albumin leakage following administration of VP2121-
130 peptide was intriguing. To better understand the nature
of CNS vascular permeability in these two strains, we eval-
uated the PIFS model by utilizing MRI. We previously
demonstrated histologically that C57BL/6 mice with PIFS
present with extensive microhemorrhage formation
throughout the brain [27]. We also reported previously
that these microhemorrhages can be scanned with T2*-
weighted MRI and that CNS vascular permeability occurs
in areas of hemorrhage [26]. We therefore determined the
extent to which brain mircrohemorrhage had occurred in
the CNSs of these two strains of mice when they were
administered VP2121-130 peptide 7 days post-TMEV infec-
tion to induce PIFS (n = 4 per group). As shown in Figure
5, 24 hours after administration of VP2121-130 peptide,
C57BL/6 mice presented with a large number of punctuate
microhemorrhages throughout the brain, consistent with
our previously published observations. We also previously
found that E7 mock peptide-treated control animals do not
present with these microhemorrhages, demonstrating that
the formation of lesions is dependent on administration of
Figure 3 Activation of an astrocyte stress response in the brain accompanies peptide-induced fatal syndrome as determined by
quantifiable glial fibrillary acidic protein Western blot analysis. C57BL/6 and 129 SvIm strain animals were infected for 7 days intracranially
with Theiler’s murine encephalomyelitis virus prior to systemic treatment with VP2121-130 peptide to induce peptide-induced fatal syndrome.
Twenty-four hours after peptide treatment the right hemispheres of mice were homogenized and analyzed for glial fibrillary acidic protein
(GFAP) levels. Shown are protein levels and normalization of GFAP to glyceraldehyde 3-phosphate dehydrogenase as a loading control. Asterisks
denote statistical significance (P < 0.05) between treatment groups. Each group consisted of six mice. One VP2121-130 peptide-treated C57BL/6
mouse had to be killed and was removed from the study.
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administered VP2121-130 peptide had markedly less detect-
able microhemorrhages as measured by T2*-weighted MRI
(P = 0.003) (Figure 5). Therefore, consistent with the 129
SvIm strain’s having lower astrocyte activation, FITC-albu-
min leakage and morbidity, this strain also presents with
reduced microhemorrhage formation following induction
of PIFS with administration of VP2121-130 peptide.
A hematopoietic factor contributes to susceptibility of
C57BL/6 mice to peptide-induced fatal syndrome
We determined that C57BL/6 mice are susceptible to
PIFS, whereas 129 SvIm mice are resistant to it. This
demonstrates that genetic background determines suscept-
ibility to this condition. To determine the extent to which
hematopoietic factors contributed to strain-related sus-
ceptibility to PIFS, lethally irradiated, resistant 129 Svlm
Figure 4 Increased vascular permeability in the brains of C57BL/6 compared to 129 SvIm mice following induction of peptide-induced
fatal syndrome. Intravenously administered fluorescein isothiocyanate (FITC)-albumin is detectable in homogenized brains of C57BL/6 mice 24
hours after administration of VP2121-130, but not E7 peptide. VP2121-130 peptide-treated 129 SvIm mice have detectable FITC-albumin leakage
compared to E7 peptide-treated controls. C57BL/6 mice have significantly higher levels of detectable FITC-albumin in the forebrain than 129
SvIm mice 24 hours after induction of peptide-induced fatal syndrome. Asterisks denote statistical significance (P < 0.05). Each group consisted
of six mice. One VP2121-130 peptide-treated C57BL/6 mouse had to be killed and was removed from the study.
Figure 5 Microhemorrhage formation in C57BL/6 mice is observable by T2*-weighted MRI (top panels). Permeability-resistant 129 SvIm
mice (bottom panels) present with reduced microhemorrhages compared to C57BL/6 mice. Raw magnetic resonance imaging scans are shown
above images analyzed using ImageJ software. Pixel value analysis revealed significantly higher microhemorrhages in C57BL/6 mice than in the
129 SvIm strain (n = 4 in each group, P = 0.003). ImageJ software was used to analyze threshold of T2*-weighted MRI lesions.
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Page 8 of 15mice were reconstituted with bone marrow from suscepti-
ble C57BL/6 mice (n = 10). 129 Svlm mice reconstituted
with autologous 129 Svlm bone marrow (n = 8) were used
as negative controls. Four weeks postreconstitution, ani-
mals were intracranially infected with TMEV. On day 7
postinfection, animals were intravenously administered
VP2121-130 peptide and assessed for the onset of PIFS as
measured by functional deficit through rotarod analysis.
129 Svlm mice reconstituted with C57BL/6 bone marrow
became susceptible to moribundity following induction of
PIFS as measured by their inability to negotiate the
rotarod. 129 Svlm mice that received autologous 129 Svlm
bone marrow remained resistant to PIFS (Figure 6). This
experiment demonstrated that a hematopoietic factor
associated with the C57BL/6 mouse genetic background
contributed to susceptibility to PIFS.
A hematopoietic factor contributes to enhanced CD8 T-
cell-initiated astrocyte glial fibrillary acidic protein
expression, microhemorrhage formation, and CNS
vascular permeability following induction of peptide-
induced fatal syndrome
The bone marrow transplant described above implied
that a hematopoietic factor contributed to TMEV-
infected animals’ becoming moribund following intrave-
nous injection with VP2121-130 peptide to induce PIFS.
We also determined that C57BL/6 mice presented with
significant astrocyte activation and increased T2*-
weighted MRI lesions indicative of microhemorrhage
formation following induction of PIFS compared to 129
SvIm mice. We therefore addressed the potential contri-
bution of hematopoietic cells to astrocyte activation and
microhemorrhage formation. 129 SvIm mice were leth-
ally irradiated and then reconstituted either with autolo-
gous 129 SvIm bone marrow to serve as negative
controls or with C57BL/6 mouse bone marrow. Eight
weeks following reconstitution both groups were
infected with TMEV and induced to undergo PIFS with
administration of VP2121-130 peptide. 129 SvIm mice
reconstituted with C57BL/6 bone marrow (n =5 )h a d
significantly higher expression of GFAP in brain lysates
compared to mice receiving 129 SvIm syngeneic bone
marrow transfer (n = 12) (Figure 7). Seven of the 129
Svlm mice reconstituted with C57BL/6 bone marrow
died before their brains were harvested to analyze
lysates for GFAP expression. Similarly, 129 SvIm mice
reconstituted with C57BL/6b o n em a r r o wp r e s e n t e d
with high T2*-weighted MRI lesion loads, indicative of
microhemorrhage formation (Figure 8, lower panels). In
contrast, 129 SvIm mice that received autologous bone
marrow had greatly reduced microhemorrhage forma-
tion (P = 0.006) (Figure 8, upper panels). Images were
acquired for four animals from each group. These
experiments demonstrate that hematopoietic factors
Figure 6 129 Svlm mice reconstituted with C57BL/6 bone marrow are unable to negotiate the rotarod. Irradiated 129 Svlm mice were
reconstituted with either autologous 129 Svlm bone marrow (n = 8) or C57BL/6 bone marrow (n = 10). Both groups were intravenously
administered VP2121-130 peptide 7 days post-Theiler’s murine encephalomyelitis virus infection. Rotarod performance is plotted as the percentage
of initial rotarod score prior to VP2121-130 peptide administration.
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Page 9 of 15expressed by the C57BL/6 mouse strain contribute to
activation of astrocytes as determined by upregulation of
GFAP and microhemorrhage formation. We have also
shown that C57BL/6 mice exhibit higher levels of CNS
vascular permeability than 129 Svlm mice as measured
by FITC-albumin leakage into the CNS (Figure 4). To
fully visualize and quantify the extent of CNS vascular
leakage and determine whether a hematopoietic factor
was contributing to this permeability, we performed bone
marrow transplants and employed three-dimensional
Figure 7 A hematopoietic factor contributes to enhanced astrocyte glial fibrillary acidic protein expression. Irradiated 129 Svlm mice
were reconstituted with either autologous 129 Svlm bone marrow (n = 12) or C57BL/6 bone marrow (n = 5). Both groups were intravenously
administered VP2121-130 peptide 7 days post-Theiler’s murine encephalomyelitis virus infection. 129 Svlm mice reconstituted with C57BL/6 bone
marrow displayed a significant increase in glial fibrillary acidic protein expression in brain lysates compared to 129 Svlm mice that received
syngeneic bone marrow transfer (P < 0.001).
Figure 8 A hematopoietic factor contributes to enhanced CD8 T-cell-induced microhemorrhage formation. The top panels show
individual 129 SvIm mice receiving autologous bone marrow. Meanwhile, 129 SvIm mice reconstituted with C57BL/6 mouse bone marrow
display significantly increased microhemorrhage formation as measured by T2*-weighted magnetic resonance imaging 24 hours post-VP2121-130
peptide administration to induce peptide-induced fatal syndrome (bottom panels). ImageJ software was used to analyze the threshold value of
T2*-weighted MRI lesions (n = 4 in each group, P = 0.003).
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Page 10 of 15volumetric analysis of gadolinium-enhanced T1-weighted
MRI studies using Analyze 10 software, which was devel-
oped by the Mayo Clinic’s Biomedical Imaging Resource
[45,46]. 129 Svlm mice reconstituted with C57BL/6 bone
marrow (n = 5) displayed a significant increase in CNS
vascular permeability after induction of PIFS (Figure 9A)
compared to 129 Svlm mice reconstituted with autolo-
gous 129 Svlm bone marrow (n =5 )( P < 0.001) (Figure
9B). The quantification of the three-dimensional volume
of gadolinium leakage from vasculature is shown in
Figure 9C. Bone marrow transfer efficacy was approxi-
mately 75% as determined by fluorescence-activated
cell-sorting analysis (data not shown). These results
demonstrate that hematopoietic factors expressed by the
C57BL/6 mouse strain also contribute to increased CNS
vascular permeability following induction of PIFS.
Discussion
In this study, we investigated the contribution of hema-
topoietic cells to antiviral CD8 T cell-initiated CNS vas-
cular permeability. We previously demonstrated that
C57BL/6 and 129 SvIm mouse strains, despite having
highly similar CD8 T-cell responses, differed in suscept-
ibility to PIFS following administration of VP2121-130
peptide. C57BL/6 mice were highly susceptible to PIFS,
whereas 129 SvIm mice, which develop a similar CD8
T-cell response, were highly resistant to this fatal syn-
drome [27]. Resistance coincided with reduced glial cell
activation and mouse survival [27]. We also observed a
significant reduction in CNS vascular permeability leak-
age in 129 SvIm mice compared to C57BL/6 mice in
this study among animals with PIFS. However, 129 SvIm
mice did exhibit some measurable vascular permeability
over mock peptide-administered controls. This result
strongly implies that low levels of vascular permeability
alone are not ultimately fatal. Rather, these results imply
that more severe BBB disruption which coincides with
microhemorrhage is what ultimately contributes to
C57BL/6 mice becoming moribund. In particular, the
microhemorrhaging observed in the hypothalamus and
brainstem would contribute to the lethality of this condi-
tion. Therefore, we put forward a working model in
which disruption of vascular integrity is fatal when it is
associated with hemorrhage in vital regions of the CNS.
A central question pertaining to the onset of hemor-
rhage is the relative contributions of blood-derived factors
versus stromal CNS tissue. We therefore sought to deter-
mine the extent to which susceptibility to PIFS is related
to hematopoietic factors through bone marrow reconstitu-
tion. The results of the experiments put forward in this
study demonstrate that functional deficit, the development
of microhemorrhaging visible as hypointense lesions on
T2*-weighted MRI scans, and the increase in CNS vascular
permeability as seen through increased volumes of gadoli-
nium leakage from vasculature on T1-weighted MRI scans
are observed in normally PIFS-resistant 129 SvIm mice
through reconstitution with C57BL/6 bone marrow. It is
possible that the increase in microhemorrhage formation
may be more severe in 129 Svlm mice that receive C57BL/
6 bone marrow than in C57BL/6 mice alone, owing to the
potential impact of irradiation, which has been shown to
alter the BBB [47,48]. Nevertheless, irradiated 129 Svlm
mice that receive C57BL/6 bone marrow display a signifi-
cant increase in microhemorrhage formation compared to
irradiated 129 Svlm mice that receive syngeneic bone mar-
row transfers. These observations support a hypothesis in
which blood-derived cells, not CNS tissue, contribute to
pathogenesis in the PIFS model of fatal immune-mediated
BBB disruption and that the onset of hemorrhage plays an
important role in this process.
Perforin expression is required for BBB disruption and
the fatal syndrome initiated by D
b:V P 2 121-130 epitope-spe-
cific CD8 T cells [24]. As put forward in this manuscript,
equivalent perforin-mediated killing among CNS-infiltrat-
ing CD8 T cells was observed in both the C57BL/6 and
129 SvIm mouse strains. This observation demonstrates
that, though perforin is critical for CD8 T-cell-initiated
BBB disruption in the C57BL/6 mouse, additional modify-
ing hematopoietic genes alter CNS vascular permeability
and the ensuing fatal syndrome. One possibility is that the
hematopoietic factors that affect CNS vascular permeabil-
ity are delivered by the perforin pathway. In addition to
initiating cytotoxicity in target cells, a more recently
revealed role for perforin includes controlling virus repli-
cation in sensory neurons without killing them [49]. There
are also an increasing number of inflammatory mediators
delivered via cytotoxic granules in addition to granzyme B
that could contribute to CNS vascular permeability [50]. A
second possibility is that hematopoietic factors which con-
tribute to BBB disruption are not related to perforin. In
addition to our studies involving CD8 T cells and perforin,
ar o l ef o rB B Bd i s r u p t i o nb y other immune cell types,
including TH17 cells, monocytes and neutrophils, has also
been put forward [21-23]. Class II gene-deficient mice are
susceptible to PIFS, thus strongly implying that CD4
T-cell subsets are not required for this syndrome to occur
[27]. Nevertheless, the contribution of these additional
immune cell subsets will be further defined in this model
system.
The list of potential hematopoietic factors in promoting
BBB disruption is extensive. VEGF is one major candidate
that may be an important mediator in CD8 T-cell-initiated
BBB disruption [25,51]. We have shown in this study that
VEGF is significantly increased in response to VP2121-130
peptide administration in 7-day TMEV-infected C57BL/6
mice, but not in 129 Svlm mice. This increase in VEGF
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Page 11 of 15Figure 9 129 Svlm mice reconstituted with C57BL/6 bone marrow display an increase in central nervous system vascular permeability
as measured by gadolinium-enhanced T1-weighted MRI scans 24 hours post-VP2121-130 peptide administration to induce peptide-
induced fatal syndrome. The extent of central nervous system vascular permeability is shown by three-dimensional transparency rendering of
gadolinium-enhancing areas in (A) 129 Svlm mice reconstituted with autologous 129 Svlm bone marrow (n =5 )o ri n(B) 129 Svlm mice
reconstituted with C57BL/6 bone marrow (n = 5). Red areas indicate subvolumes with gadolinium enhancement. The overall thickness of
underlying gadolinium enhancement and the distance from the surface influence the intensity of these areas. (C) Quantification of the three-
dimensional volume of vascular permeability in each group. 129 Svlm mice reconstituted with C57BL/6 bone marrow exhibit a significant
increase in vascular permeability compared to 129 Svlm mice reconstituted with autologous 129 Svlm bone marrow (P < 0.001).
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Page 12 of 15may promote increased CNS vascular permeability, which
is also seen in C57BL/6 mice induced to develop PIFS, but
not in 129 Svlm mice. In support of this hypothesis, we
previously showed that inhibiting VEGF causes a reduc-
tion in CNS vascular permeability and promotes survival
[25]. Therefore, it will be essential to further investigate
this potential mechanism of CD8 T-cell-initiated BBB dis-
ruption. Other potential factors that may contribute to
BBB disruption are cytokines, including IL-2, TNF-a,l y m -
photoxins and IL-6 [7,52]. Various chemokines and matrix
metalloproteases (MMPs) are additional inflammatory
mediators reported to alter BBB permeability [53,54]. A
role for death receptors in inducing a permeable state
among endothelial cells through promoting upregulation
of MMP9 in model systems has also been put forward
[55]. Given the large number of candidate hematopoietic
factors that could confer resistance and susceptibility to
T-cell-mediated BBB disruption, the most robust approach
to defining the critical genetic factors that contribute to
CNS vascular permeability in the PIFS model will involve
gene mapping. The experiments conducted in this study
set the stage for such an analysis because rotarod perfor-
mance, astrocyte activation and CNS vascular permeability
are significantly different between the C57BL/6 and 129
SvIm mouse strains in this model. This model system will
therefore enable a comprehensive genetic analysis to
define quantitative trait loci that map to each of these
characteristics.
Conclusions
This study demonstrates the importance of the hemato-
poietic compartment in altering glial cell activation, vas-
cular permeability and the onset of microhemorrhaging
in the brain. This is significant because it demonstrates
that the resulting fatal syndrome is not dictated by stro-
mal tissue, but rather by blood-derived cells. Therefore,
a concerted effort to define hematopoietic factors
responsible for immune-mediated CNS vascular perme-
ability will ultimately result in therapeutic strategies to
suppress or induce opening of the BBB in neurological
diseases.
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